This finding combined with the reduction in glioma cell growth caused by a reduction in Bcl-2 expression after PAX8-knockdown and the small amount of PAX8 expression in normal brain tissue suggests that PAX8 would be a suitable target pathway for glioma therapy. Here, BCL2 is linked to central nervous system cancer.